Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral® vs sandimmune®

International Journal of Dermatology

Volumn 36, Issue SUPPL. 1, 1997, Pages 1-6

  Choc, Miles G ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOSPORIN A; DICLOFENAC; DIGOXIN; DILTIAZEM; ERYTHROMYCIN; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; METHOTREXATE; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

CLINICAL ARTICLE; CONFERENCE PAPER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG INDUCED DISEASE; FOOD DRUG INTERACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PSORIASIS; SKIN DISEASE;

EID: 0031447015     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.36.s1.2.x     Document Type: Conference Paper

References (13)

1. Borel JF. Mechanism of action and rationale for cyclosporin A in psoriasis. Br J Dermatol 1990; 122 (Suppl. 36): 5-12.
2. Meinzer A, Mueller EA, Niese D, et al. Improved oral absorption of cyclosporine by using Neoral, a microemulsion formulation. In: Lieberman R, Mukherjee A, eds. Principles of Drug Development in Transplantation and Autoimmunity. Austin, TX: R.G. Landes, 1996: 259-267.
3. Fahr A, Hiestand P, Ryffel B. Studies on the biologic activities of Sandimmune metabolites in humans and in animal models: review and original experiments. Transplant Proc 1990; 22: 116-124.
4. Neoral®. Physicians' Desk Reference, 51st edn. Montvale, NJ: Medical Economics, 1997: 2405-2409.
5. Elder CA, Moore M, Chang CT, et al. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 1995; 35: 865-875.
6. Sandoz Study No. SF-07. A study to compare the steady state pharmacokinetics of Sandimmune (SIM-SGC) and Sandimmnne Neoral (SIM-NOF) in patients with psoriasis. Report on file at Novartis Pharmaceuticals Corporation, East Hanover, NJ.
7. Choc MG, Smith HT, Gibbons ME, et al. Cyclosporine bioavailability in severe psoriasis patients using Neoral, a new microemulsion formulation. Presented at the International Congress on Immunointervention, June 20-22, Rome, Italy, 1996: 51.
8. Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharmacol Res 1994; 11: 301-304.
9. Katz HI. Dermatologist's Guide to Adverse Therapeutic Interactions. New York: Lippincott-Raven, 1996: 50-55, 140-146.
10. Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.
11. Honcharik N. The effect of food on cyclosporine absorption. Clin Biochem 1991; 24: 89-92.
12. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485-491.
13. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 137-141.